Vladimir Kalinichenko
Professor and Director
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
About
Vladimir Kalinichenko is a Professor and Director at The University of Arizona College of Medicine Phoenix, USA. His research primarily focuses on gene therapy, endothelial progenitor cells, and mechanisms affecting lung development and repair. Recent articles highlight his work on minicircle production for gene therapy, the role of macrophage transplantation in enhancing cell therapy efficacy, and the identification of key enhancers involved in alveolar capillary dysplasia.
Articles (8)
Year:
2026
Year:
2025
Recent studies demonstrated that transplantation of lung-resident endothelial progenitor cells (EPC) is an effective therapy in mouse model of bronchopulmonary dysplasia (BPD). However, key factors regulating the efficacy of EPC are unknown. Herein, we demonstrate that transplantation of tissue-resident alveolar macrophages (rAM) increases CXCL12 expression in neonatal mouse lungs. rAM are required for retention of donor EPC in hyperoxia-injured lungs. Co-transplantation of rAM and EPC improves the efficacy of EPC therapy in mouse BPD model.
Year:
2024
Mutations in the FOXF1 gene, a key transcriptional regulator of pulmonary vascular development, cause Alveolar Capillary Dysplasia with Misalignment of Pulmonary Veins, a lethal lung disease affecting newborns and infants. Identification of new FOXF1 upstream regulatory elements is critical to explain why frequent non-coding FOXF1 deletions are linked to the disease. Herein, we use multiome single-nuclei RNA and ATAC sequencing of mouse and human patient lungs to identify four conserved endothelial and mesenchymal FOXF1 enhancers. We demonstrate that endothelial FOXF1 enhancers are autoactivated, whereas mesenchymal FOXF1 enhancers are regulated by EBF1 and GLI1. The cell-specificity of FOXF1 enhancers is validated by disrupting these enhancers in mouse embryonic stem cells using CRISPR/Cpf1 genome editing followed by lineage-tracing of mutant embryonic stem cells in mouse embryos using blastocyst complementation. This study resolves an important clinical question why frequent non-coding FOXF1 deletions that interfere with endothelial and mesenchymal enhancers can lead to the disease.
Year:
2024
Rationale Approximately 80% of patients with non-familial pulmonary arterial hypertension (PAH) lack identifiable pathogenic genetic variants. While most genetic studies of PAH have focused on predicted loss-of-function variants, recent approaches have identified ultra-rare missense variants associated with the disease. FOXF1 encodes a highly conserved transcription factor, essential for angiogenesis and vasculogenesis in human and mouse lungs. Objectives We identified a rare FOXF1 missense coding variant in two unrelated probands with PAH. FOXF1 is an evolutionarily conserved transcription factor required for lung vascular development and vascular integrity. Our aims were to determine the frequency of FOXF1 variants in larger PAH cohorts compared to the general population, study FOXF1 expression in explanted lung tissue from PAH patients versus control (failed-donor) lungs, and define potential downstream targets linked to PAH development. Methods Three independent, international, multicenter cohorts were analyzed to evaluate the frequency of FOXF1 rare variants. Various composite prediction models assessed the deleteriousness of individual variants. Bulk RNA sequencing datasets from human explanted lung tissues were compared to failed-donor controls to determine FOXF1 expression. Bioinformatic tools identified putative FOXF1 binding targets, which were orthogonally validated using mouse ChIP-seq datasets. Measurements and Main Results Seven novel or ultra-rare missense coding variants were identified across three patient cohorts in different regions of the FOXF1 gene, including the DNA binding domain. FOXF1 expression was dysregulated in PAH lungs, correlating with disease severity. Histological analysis showed heterogeneous FOXF1 expression, with the lowest levels in phenotypically abnormal endothelial cells within complex vascular lesions in PAH samples. A hybrid bioinformatic approach identified FOXF1 downstream targets potentially involved in PAH pathogenesis, including BMPR2 . Conclusions Large genomic and transcriptomic datasets suggest that decreased FOXF1 expression or predicted dysfunction is associated with PAH.
Year:
2024
Year:
2022
Year:
2022
Year:
2021
Collaborators (11)
Jurjan Aman
VU University Medical Center
William Zacharias
Associate Professor
Cincinnati Children's Hospital Medical Center
Michael Pauciulo
Assistant Professor
Cincinnati Children's Hospital Medical Center
Tatiana Kalin
Professor
Cincinnati Children's Hospital Medical Center
Christopher Rhodes
Lecturer in Digital Media Production
University College London
Arjan C Houweling
Clinical Geneticist, Associate Professor
Amsterdam University Medical Centers
Stefan Gräf
Research Professor of Computational Genomics & Genomic Medicine
University of Cambridge
Wendy Chung
Kennedy Family Professor
Boston Children's Hospital
Harm Jan Bogaard
Professor of Medicine
VU medisch centrum
Jose Gomez-Arroyo
Assistant Professor
University of Cincinnati
Francis McCormack
Division Chief
University of Cincinnati
Make your next move.
Prepare your application
Review drafts before you send them.